Anti-TPC14/ C7orf43 monoclonal antibody

Anti-TPC14/ C7orf43 antibody for FACS & in-vivo assay

Target products collectionGo to C7orf43/C7orf43 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-MP2029-Ab-1/ GM-Tg-hg-MP2029-Ab-2Anti-Human C7orf43 monoclonal antibodyHuman
GM-Tg-rg-MP2029-Ab-1/ GM-Tg-rg-MP2029-Ab-2Anti-Rat C7orf43 monoclonal antibodyRat
GM-Tg-mg-MP2029-Ab-1/ GM-Tg-mg-MP2029-Ab-2Anti-Mouse C7orf43 monoclonal antibodyMouse
GM-Tg-cynog-MP2029-Ab-1/ GM-Tg-cynog-MP2029-Ab-2Anti-Cynomolgus/ Rhesus macaque C7orf43 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-MP2029-Ab-1/ GM-Tg-felg-MP2029-Ab-2Anti-Feline C7orf43 monoclonal antibodyFeline
GM-Tg-cang-MP2029-Ab-1/ GM-Tg-cang-MP2029-Ab-2Anti-Canine C7orf43 monoclonal antibodyCanine
GM-Tg-bovg-MP2029-Ab-1/ GM-Tg-bovg-MP2029-Ab-2Anti-Bovine C7orf43 monoclonal antibodyBovine
GM-Tg-equg-MP2029-Ab-1/ GM-Tg-equg-MP2029-Ab-2Anti-Equine C7orf43 monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-MP2029-Ab-1/ GM-Tg-hg-MP2029-Ab-2; GM-Tg-rg-MP2029-Ab-1/ GM-Tg-rg-MP2029-Ab-2;
GM-Tg-mg-MP2029-Ab-1/ GM-Tg-mg-MP2029-Ab-2; GM-Tg-cynog-MP2029-Ab-1/ GM-Tg-cynog-MP2029-Ab-2;
GM-Tg-felg-MP2029-Ab-1/ GM-Tg-felg-MP2029-Ab-2; GM-Tg-cang-MP2029-Ab-1/ GM-Tg-cang-MP2029-Ab-2;
GM-Tg-bovg-MP2029-Ab-1/ GM-Tg-bovg-MP2029-Ab-2; GM-Tg-equg-MP2029-Ab-1/ GM-Tg-equg-MP2029-Ab-2
Products NameAnti-C7orf43 monoclonal antibody
Formatmab
Target NameC7orf43
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-C7orf43 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenProducts DevelopingMulti-species TPC14/ C7orf43 VLP (virus-like particle) (Products Developing)


    Target information

    Target IDGM-MP2029
    Target NameC7orf43
    Gene ID55262,231807,288545,711262,608066,101098674,511902,100147030
    Gene Symbol and SynonymsC13H7orf43,C25H7orf43,C3H7orf43,C6H7orf43,C7orf43,CE3H7orf43,MAP11,MCPH25,RGD1305455,TRAPPC14
    Uniprot AccessionQ8WVR3
    Uniprot Entry NameTPC14_HUMAN
    Protein Sub-locationTransmembrane Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000146826
    Target ClassificationN/A

    The target: C7orf43, gene name: C7orf43, also named as . Enables alpha-tubulin binding activity. Involved in cilium assembly and regulation of cell population proliferation. Located in several cellular components, including microtubule cytoskeleton; midbody; and plasma membrane. Part of TRAPPII protein complex. Implicated in primary autosomal recessive microcephaly. [provided by Alliance of Genome Resources, Apr 2022].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.